Comparative pharmacokinetics of the carbapenems: clinical implications.
about
CarbapenemsThe pharmacokinetics and pharmacodynamics of the carbapanemes: focus on doripenemClinical review: balancing the therapeutic, safety, and economic issues underlying effective antipseudomonal carbapenem useClinical Validation of Therapeutic Drug Monitoring of Imipenem in Spent Effluent in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Pilot StudyPopulation pharmacokinetics of doripenem based on data from phase 1 studies with healthy volunteers and phase 2 and 3 studies with critically ill patients.Ertapenem: a new carbapenem.Population pharmacokinetics of imipenem in critically ill patients with suspected ventilator-associated pneumonia and evaluation of dosage regimensMicrodialysis study of imipenem distribution in skeletal muscle and lung extracellular fluids of Acinetobacter baumannii-infected ratsPenetration of ertapenem into muscle measured by in vivo microdialysis in mechanically ventilated patients.Assays for determination of ertapenem for applications in therapeutic drug monitoring, pharmacokinetics and sample stability.A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics?Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance.Ertapenem: review of a new carbapenem.Modeling approach to characterize intraocular doripenem pharmacokinetics after intravenous administration to rabbits, with tentative extrapolation to humansPotential impact of vancomycin pulmonary distribution on treatment outcomes in patients with methicillin-resistant Staphylococcus aureus pneumonia.Influence of pharmacokinetics/pharmacodynamics of antibacterials in their dosing regimen selection.Intra-abdominal infections: considerations for the use of the carbapenems.Ertapenem: the new carbapenem 5 years after first FDA licensing for clinical practice.Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenemPharmacodynamic variability beyond that explained by MICs.Zafirlukast inhibits complexation of Lsr2 with DNA and growth of Mycobacterium tuberculosisPooled population pharmacokinetic model of imipenem in plasma and the lung epithelial lining fluidReassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignanciesLack of age and gender effects on single-dose pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.Meropenem pharmacokinetics in the newborn.Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers.The strategy of antibiotic use in critically ill neutropenic patientsAntimicrobial treatment of febrile neutropenia: pharmacokinetic-pharmacodynamic considerations.Role of therapeutic drug monitoring in pulmonary infections: use and potential for expanded use of dried blood spot samples.Evaluation of restricted antibiotic use in a hospital in Romania.High target attainment for β-lactam antibiotics in intensive care unit patients when actual minimum inhibitory concentrations are applied.Pharmacokinetic Modeling and Limited Sampling Strategies Based on Healthy Volunteers for Monitoring of Ertapenem in Patients with Multidrug-Resistant Tuberculosis.High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii.Pharmacokinetic study of meropenem in healthy beagle dogs receiving intermittent hemodialysis.In vitro and in vivo activity of biapenem against drug-susceptible and rifampicin-resistant Mycobacterium tuberculosis.Pharmacokinetics of CS-023 (RO4908463), a novel parenteral carbapenem, in healthy male Caucasian volunteers.Extended infusion versus intermittent infusion of imipenem in the treatment of ventilator-associated pneumonia.Pharmacokinetics of ertapenem following intravenous and subcutaneous infusions in patients.Augmented Renal Clearance in Critical Illness: An Important Consideration in Drug Dosing.Population pharmacokinetics of ertapenem in juvenile and old rats.
P2860
Q28286055-3C83451E-F202-4D74-B3A2-3E6FD3968DAEQ28289744-2F32FF68-ABBB-4493-AFB4-EB303FED9265Q28299749-B1CA84C8-893A-498C-8A86-24BD9D385153Q28551453-EFA18B7C-7332-4E82-AD66-2B5637843A34Q33553063-176118E8-626E-4019-AC49-80525D182093Q34481516-B78F51CA-CE4A-4D07-A3B6-2DF4BB9C76FAQ34570886-1B00BAAE-EDCE-48B4-88DE-E99FF4464735Q34680635-632CB41D-8455-4010-8389-E67576D226D8Q35065899-D0123F02-DA25-40C3-A4FC-E1BE3589EDEDQ35218071-EF8161C4-6931-4ED8-808A-43E525D55DF2Q35617587-79E72D54-384A-49CF-ADB8-9CBEB9EB2962Q35960788-616C9973-4922-4718-B64B-5701ACDB0509Q36066200-1AEA8A88-0A37-4BAF-BD8D-429FDABDA526Q36086333-06A9CE5F-80AA-4C1B-8EE1-E40114C5CCDEQ36428418-5FCA8BF8-8595-4B1F-B693-FAE5965F1967Q36505518-7BAF737E-D096-421F-9F44-16B4DA7D217DQ36719679-7421E7B2-BFA3-4344-A2A6-4347BF98A781Q36719706-01B5A9D0-1951-4F98-8BB6-912FD2DE8F89Q36744822-C98E468C-1203-481A-BAEE-93BC888B7F21Q36757639-54EBD00E-9B2B-43DD-9447-C2AB4D73DB5BQ36785897-8A83EDA6-9DDB-4B5E-9DCA-4BD8826FEF8FQ36924714-AB558F57-99B5-4A64-953C-407CC14DB517Q37072039-AC314514-43E6-45A2-9F8A-7595097CCD6EQ37184455-D36E8D92-CE71-4A68-B2B0-536A52CA3004Q37333159-95354362-E151-4FEF-BC6B-B11435D5B65DQ37568571-D7A71C0C-A2D7-4FA8-91F5-190A557B047EQ37929895-EBE3BBC0-F868-4CAA-BBFC-A6731238935FQ38117578-D2A4283B-9B61-4727-B753-65B76A91AEEAQ38369608-6488562D-561B-49CA-A44D-E211754EE46EQ38400333-835656C3-AF3E-4B53-8BE0-BBE38365EDBCQ38798373-E11430EF-5428-4E1C-8FA0-1394BAF361F1Q38991205-46B2FD6F-CC24-455A-A227-37E1AA992F36Q39170967-84F2F7D6-418A-447C-B55A-E5068FB2401DQ39682907-F57D25ED-CE0A-49A8-A51F-F5FAA4F78C69Q40187337-AF2516E9-3A31-4AC9-8186-5531C2D01965Q40903305-59CF83F9-4B9F-46E6-A444-A57BF23C0CDFQ41354782-6350770A-C502-475D-86EC-AB9F4093B119Q41876999-E5A047E3-35EB-44A3-926E-1D84BE48BD76Q42228348-71B09F1F-FE97-4ED0-B99A-E26A53973C6CQ42264085-FEE40D31-683A-47B8-9FFA-32CD8D37EB15
P2860
Comparative pharmacokinetics of the carbapenems: clinical implications.
description
2000 nî lūn-bûn
@nan
2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Comparative pharmacokinetics of the carbapenems: clinical implications.
@ast
Comparative pharmacokinetics of the carbapenems: clinical implications.
@en
Comparative pharmacokinetics of the carbapenems: clinical implications.
@nl
type
label
Comparative pharmacokinetics of the carbapenems: clinical implications.
@ast
Comparative pharmacokinetics of the carbapenems: clinical implications.
@en
Comparative pharmacokinetics of the carbapenems: clinical implications.
@nl
prefLabel
Comparative pharmacokinetics of the carbapenems: clinical implications.
@ast
Comparative pharmacokinetics of the carbapenems: clinical implications.
@en
Comparative pharmacokinetics of the carbapenems: clinical implications.
@nl
P2093
P2860
P1476
Comparative pharmacokinetics of the carbapenems: clinical implications.
@en
P2093
P2860
P304
P356
10.2165/00003088-200039030-00002
P577
2000-09-01T00:00:00Z
P6179
1016041966